URL path: Index page // Plasminogen Activator Inhibitor 2 (PAI-2), Mutation Ser413Cys

Plasminogen Activator Inhibitor 2 (PAI-2), Mutation Ser413Cys

This assay detects the presence of the Ser413Cys mutation in the PAI-2 gene.

Plasminogen activator inhibitor-1 (PAI-1) is a key component in regulating the fibrinolytic mechanism. It binds to the tissue plasminogen activator (tPA) and inhibits the conversion of plasminogen to plasmin, which results in a decrease in fibrinolysis (ie blood clotting). PAI-1 is encoded by the SERPINE1 gene located on chromosome 7.

The other form of PAI, PAI-2, is secreted by the placenta only and is present in significant quantities only during pregnancy, indicating a potential role in the process of placenta maintenance and/or fetal development and which decreased significantly during the last 2 weeks of pregnancy. PAI-2 is encoded by the SERPINB2 gene located on chromosome 18. Haplotype A, which contains the Ser413 allele, has been associated with an increased risk of myocardial infarction.



Important Note

Laboratory test results are the most important parameter for the diagnosis and monitoring of all pathological conditions. 70%-80% of diagnostic decisions are based on laboratory tests. The correct interpretation of laboratory results allows a doctor to distinguish "healthy" from "diseased".

Laboratory test results should not be interpreted from the numerical result of a single analysis. Test results should be interpreted in relation to each individual case and family history, clinical findings, and the results of other laboratory tests and information. Your personal physician should explain the importance of your test results.

At Diagnostiki Athinon we answer any questions you may have about the test you perform in our laboratory and we contact your doctor to get the best possible medical care.

Additional information
Share it